再鼎医药:2024年产品收入净额增加49%,亏损净额减少23%

界面
28 Mar

再鼎医药3月28日早间发布2024年度业绩公告,2024年产品收入净额增加1.309亿美元(或49%)至3.976亿美元,主要受卫伟迦®自2023年9月上市及于2024年1月被纳入国家医保目录以来销售额增加,同时亦得益于则乐®及纽再乐®的销售额增加所推动。研发开支减少3140万美元(或12%)至2.345亿美元,主要是受现有研究项目进展的影响,部分被许可费用增加所抵销。销售、一般及行政开支增加...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10